(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 12 May 2005 (12.05.2005)

PCT

(10) International Publication Number WO 2005/042567 A1

- (51) International Patent Classification7: C07K 7/06. A61K 31/436, C07K 1/00, 5/04, A61K 38/04, A61L 31/08, 31/16, A61P 37/00, C07D 498/14
- (21) International Application Number:

PCT/CA2004/001918

(22) International Filing Date:

3 November 2004 (03.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/516,273

3 November 2003 (03.11.2003)

- (71) Applicant (for all designated States except US): AL-

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,



(71) Applicant (for all designated States except US): ALTACHEM PHARMA LTD. (CA/CA): 9411-20th Avenue, Edmonton, Alberta T6N 1E5 (CA).

(72) Inventors; and
(73) Inventors; and
(75) Inventors/Applicants (for US only): SHARMA, Sanjay, K. (IN/CA): 204C, 3624-119 Street, Edmonton, Alberta T6J 2X6 (CA). WOO, Thomus (CA/CA); 130 Leigh Cr., Edmonton, Alberta T6R 2S8 (CA), NAICKER, Selvaraj (CA/CA); 3304-117 Street, Edmonton, Alberta T6J 3J4 (CA).

(74) Agent: OGILVY RENAULT; Suite 1600, 45 O'Connor Street, Ottawa, Ontario K1P 1A4 (CA).

(75) Abstract: The present invention relates to new rapamycin derivatives for the inhibition of cell proliferation. The compounds and advantageously target two proteins in dividing cells and interfere with cell cycle. There is thus provided derivatives of rapamycin in which the 42 position of rapamycin is linked to an amino acid or a peptide through a carbamate ester linkage. These rapamycin derivatives can be used to inhibit the cell cycle and are therefore useful for treating cell derivatives can be synthesized by reacting 42-O-(4-Nitrophenoxycarbonyl) rapamycin and an amino acid or a free amino peptide under basic conditions. These rapamycin derivatives can be used to inhibit the cell cycle and are therefore useful for treating cell proliferation disorders.

